INDIANAPOLIS, May 29, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data showing that FORTEO significantly increased lumbar spine volumetric bone mineral density (vBMD) ...

In December 2025, Amphastar Pharmaceuticals announced that the FDA approved its abbreviated new drug application for a teriparatide injection prefilled pen, deemed bioequivalent and therapeutically ...

Forteo (teriparatide) is a brand-name medication that doctors may prescribe to treat osteoporosis. The drug uses proteins to enhance bone strength and promote the development of new bone tissue. You ...

Please provide your email address to receive an email when new articles are posted on . Teva Pharmaceuticals announced FDA approval of a generic version of Forteo in ...

INDIANAPOLIS Eli Lilly has begun marketing a device for injecting its drug Forteo, the company announced Wednesday. Lilly said the Forteo Delivery Device was designed to make injection of the drug ...

Teva Pharmaceuticals has received the Food and Drug Administration’s approval for generic Forteo. The product is expected to be available in the coming weeks. “We are thrilled to receive the ...

Eli Lilly’s blockbuster drug for osteoporosis, Forteo, could face generic competition from Indian drugmaker Sun Pharmaceuticals if the company can get a federal judge to declare that a Lilly patent ...

It was only a few days ago that Radius Health came out with Tymlos, a new competitor to Eli Lilly osteoporosis medication Forteo. And one prominent cost watchdog already has something to say about it.

today announced new data showing that FORTEO significantly increased lumbar spine volumetric bone mineral density (vBMD) compared to risedronate in men with glucocorticoid-induced osteoporosis.

Forteo (teriparatide) is a brand-name drug that doctors prescribe for some people with osteoporosis. It contains proteins that strengthen bones and stimulate new bone growth. A typical prescription is ...